| Ticker | IMGN |
|---|---|
| ISIN | US45253H1014 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. ...
El precio actual de ImmunoGen, Inc. (IMGN) es de 31,24 , con una variación del 0,02%.
ImmunoGen, Inc. opera en el sector Healthcare, industria Biotechnology.
Compara brokers con acceso a las principales bolsas internacionales, con bajas comisiones, custodia y herramientas de análisis para invertir en acciones.
Compara brokers para acciones